303 related articles for article (PubMed ID: 28823933)
1. Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.
Stanic J; Mellone M; Napolitano F; Racca C; Zianni E; Minocci D; Ghiglieri V; Thiolat ML; Li Q; Longhi A; De Rosa A; Picconi B; Bezard E; Calabresi P; Di Luca M; Usiello A; Gardoni F
Neurobiol Dis; 2017 Dec; 108():54-64. PubMed ID: 28823933
[TBL] [Abstract][Full Text] [Related]
2. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
Errico F; Bonito-Oliva A; Bagetta V; Vitucci D; Romano R; Zianni E; Napolitano F; Marinucci S; Di Luca M; Calabresi P; Fisone G; Carta M; Picconi B; Gardoni F; Usiello A
Exp Neurol; 2011 Dec; 232(2):240-50. PubMed ID: 21946266
[TBL] [Abstract][Full Text] [Related]
3. Rabphilin 3A retains NMDA receptors at synaptic sites through interaction with GluN2A/PSD-95 complex.
Stanic J; Carta M; Eberini I; Pelucchi S; Marcello E; Genazzani AA; Racca C; Mulle C; Di Luca M; Gardoni F
Nat Commun; 2015 Dec; 6():10181. PubMed ID: 26679993
[TBL] [Abstract][Full Text] [Related]
4. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
Fiorentini C; Rizzetti MC; Busi C; Bontempi S; Collo G; Spano P; Missale C
Mol Pharmacol; 2006 Mar; 69(3):805-12. PubMed ID: 16365282
[TBL] [Abstract][Full Text] [Related]
5. NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology.
Mellone M; Zianni E; Stanic J; Campanelli F; Marino G; Ghiglieri V; Longhi A; Thiolat ML; Li Q; Calabresi P; Bezard E; Picconi B; Di Luca M; Gardoni F
Neurobiol Dis; 2019 Jan; 121():338-349. PubMed ID: 30261285
[TBL] [Abstract][Full Text] [Related]
6. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia.
Gardoni F; Picconi B; Ghiglieri V; Polli F; Bagetta V; Bernardi G; Cattabeni F; Di Luca M; Calabresi P
J Neurosci; 2006 Mar; 26(11):2914-22. PubMed ID: 16540568
[TBL] [Abstract][Full Text] [Related]
7. Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
Smith LM; Parr-Brownlie LC; Duncan EJ; Black MA; Gemmell NJ; Dearden PK; Reynolds JN
Neuroscience; 2016 Jun; 324():238-51. PubMed ID: 26968766
[TBL] [Abstract][Full Text] [Related]
8. NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients.
Mellone M; Stanic J; Hernandez LF; Iglesias E; Zianni E; Longhi A; Prigent A; Picconi B; Calabresi P; Hirsch EC; Obeso JA; Di Luca M; Gardoni F
Front Cell Neurosci; 2015; 9():245. PubMed ID: 26217176
[TBL] [Abstract][Full Text] [Related]
9. Rabphilin-3A undergoes phase separation to regulate GluN2A mobility and surface clustering.
Yang L; Wei M; Wang Y; Zhang J; Liu S; Liu M; Wang S; Li K; Dong Z; Zhang C
Nat Commun; 2023 Jan; 14(1):379. PubMed ID: 36693856
[TBL] [Abstract][Full Text] [Related]
10. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
[TBL] [Abstract][Full Text] [Related]
11. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
Marin C; Bonastre M; Aguilar E; Jiménez A
Synapse; 2011 Oct; 65(10):1080-6. PubMed ID: 21484883
[TBL] [Abstract][Full Text] [Related]
12. Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Martinez AA; Morgese MG; Pisanu A; Macheda T; Paquette MA; Seillier A; Cassano T; Carta AR; Giuffrida A
Neurobiol Dis; 2015 Feb; 74():295-304. PubMed ID: 25486547
[TBL] [Abstract][Full Text] [Related]
13. Rabphilin-3A as a novel target to reverse α-synuclein-induced synaptic loss in Parkinson's disease.
Ferrari E; Scheggia D; Zianni E; Italia M; Brumana M; Palazzolo L; Parravicini C; Pilotto A; Padovani A; Marcello E; Eberini I; Calabresi P; Diluca M; Gardoni F
Pharmacol Res; 2022 Sep; 183():106375. PubMed ID: 35918045
[TBL] [Abstract][Full Text] [Related]
14. Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD.
Picconi B; Ghiglieri V; Bagetta V; Barone I; Sgobio C; Calabresi P
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S145-9. PubMed ID: 18583173
[TBL] [Abstract][Full Text] [Related]
15. Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats.
Billet F; Costentin J; Dourmap N
Exp Neurol; 2012 Aug; 236(2):339-50. PubMed ID: 22575599
[TBL] [Abstract][Full Text] [Related]
16. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
[TBL] [Abstract][Full Text] [Related]
17. Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
Song L; Zhang Z; Hu R; Cheng J; Li L; Fan Q; Wu N; Gan J; Zhou M; Liu Z
Drug Des Devel Ther; 2016; 10():547-55. PubMed ID: 26893543
[TBL] [Abstract][Full Text] [Related]
18. BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
Tronci E; Napolitano F; Muñoz A; Fidalgo C; Rossi F; Björklund A; Usiello A; Carta M
Exp Neurol; 2017 Nov; 297():73-81. PubMed ID: 28757258
[TBL] [Abstract][Full Text] [Related]
19. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
Chen L; Togasaki DM; Langston JW; Di Monte DA; Quik M
Neuroscience; 2005; 132(2):409-20. PubMed ID: 15802193
[TBL] [Abstract][Full Text] [Related]
20. The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
Bordia T; McIntosh JM; Quik M
J Neurochem; 2013 Apr; 125(2):291-302. PubMed ID: 23373725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
